3062 Ceritinib following crizotinib in ALK-positive (+) advanced NSCLC patients (pts): Results from the French Temporary Authorization for Use (ATU) experience

Saved in:
Bibliographic Details
Published inEuropean journal of cancer (1990) Vol. 51; pp. S616 - S617
Main Authors Cadranel, J., Cortot, A., Lena, H., Mennecier, B., Do, P., Dansin, E., Mazieres, J., Chouaid, C., Perol, M., Barlesi, F.
Format Journal Article
LanguageEnglish
Published Elsevier Ltd 01.09.2015
Subjects
Hematology, Oncology and Palliative Medicine
Online AccessGet full text
ISSN0959-8049
1879-0852
DOI10.1016/S0959-8049(16)31704-X

Cover

More Information
ISSN:0959-8049
1879-0852
DOI:10.1016/S0959-8049(16)31704-X